Jaeb Center for Health Research

“There are no committees with authority to act on behalf of the governing body.”

“A complete copy of form 990 including all supporting schedules will be provided to the board of directors at its annual meeting for review and acceptance prior to filing.”

“Any board director, corporate officer, or member of a board committee who has direct or indirect financial interest, as defined below, is an interested person. If a person is an interested person with respect to any affiliate or subsidiary of the corporation, he/she is an interested person with respect to the corporation and all affiliated or subsidiary entities. A conflict of interest shall be deemed to exist at any time when an interest held, including without limitation a financial interest, or relationship maintained by an interested person, prohibits or inhibits, or potentially prohibits or inhibits, the interested person from exercising independent judgment in the best interests of the corporation. A conflict of interest shall not exist if resulting solely from the normal conduct of activities and business by and between the corporation or other affiliates of the corporation. An interested person must disclose the existence of the facts and circumstances of any conflict of interest or conflict of loyalty to the appropriate governance body with respect to any action or proposed action that gives rise to a conflict of interest or conflict of loyalty. Disclosure must be made to the board of directors or the board of directors committee as appropriate to the circumstances. After disclosure of the conflict of interest or conflict of loyalty and all material facts related thereto, and after any discussion with the interested person, the interested person shall leave any board of directors or committee meeting while the determination of a conflict of interest is discussed and voted upon. The remaining board directors or committee members shall decide if a conflict of interest exists. In the case of a disclosure to a committee, the committee may refer the matter for decision to the board of directors. Pending review and resolution by the board of directors or board committee, the interested person shall leave during any deliberations or action concerning the matter that gives rise to a conflict of interest.”

“The board of directors shall annually review and approve the compensation of the corporate officers, any key employees (as defined by the irs), and the next five highest compensated employees as listed on the organization's prior year form 990. It is the board's intention that this policy and its associated procedures will meet the rebuttable presumption test under irc 4958 and treasury regulation 53.4958-6. The purpose of the annual review is to ensure that the compensation program falls within a reasonable range of competitive practices for comparable positions among similarly situated organizations. The board will keep robust minutes of its deliberations and decisions, the president's reports, the corporate treasurer's reports, and any other supporting documentation that it relies on for its compensation decisions. All these documents will be delivered to the corporate secretary promptly after the board meeting for entry into the corporate books and records. The process described here was last completed in 2024.”

“The audited financial statements, form 990s, and form 1023 are made available to the public on the organization's website and upon request.”

“During 2024, jchr was engaged in 50 clinical studies, which culminated in 51 scientific publications and 50 presentations at prominent national and international conferences. In 2024, jchr received grants from the national institutes of health (8), helmsley charitable trust (10), breakthrough t1d (6), foundation fighting blindness (6), cystic fibrosis foundation (5), food and drug administration (1), and national institute for health and care research (1). Collaborations with industry continues to be an integral part of our work. Jchr was engaged in collaborations with 14 industry partners spanning 21 studies, including 9 investigator initiated studies. Several studies are funded by multiple sources. For example, one clinical trial evaluating fenofibrate for diabetic retinopathy is a large collaboration with funds provided by the national institutes of health (national eye institute and national institute of diabetes and digestive and kidney disease), breakthrough t1d, helmsley charitable trust, and roche. Jchr also self-funded one study and numerous statistical analysis projects using datasets from previously completed studies. Among approximately 2,845 entities receiving nih funding in 2024, jchr ranks in the top 9 percent. Out of approximately 65,000 nih grants awarded in 2024, jchr had the 178th- (top 0.3 percent) and 312th- (top 0.47 percent) largest grants (source: blue ridge institute for medical research, 2024). Jchr's studies in 2024 led to several high-impact findings with clinical and regulatory implications. Notable results include: diabetes studies: 1. Secure-t2d trial results: this study demonstrated that the omnipod 5 automated insulin delivery system was safe and effective for adults with type 2 diabetes, helping to optimize glucose control. The results of the trial lead to fda approval of omnipod 5 for patients with type 2 diabetes. 2. Evaluation of ultra-rapid lispro insulin with control-iq technology: a multicenter study evaluated the use of ultra-rapid lispro (urli) insulin in combination with control-iq technology across adults, adolescents, and children with type 1 diabetes. The results showed that urli insulin improved postprandial glucose control and enhanced overall time in range, highlighting its effectiveness as part of an advanced automated insulin delivery system. This study led to tandem diabetes care, inc., obtaining european union (eu) clearance for the t:slim x2 insulin pump with control-iq automated insulin delivery (aid) technology with the use of eli lilly and company's lyumjev (insulin lispro-aabc injection) ultra-rapid-acting insulin. 3. Impact of cgm on pregnancy outcomes: the study demonstrated that continuous glucose monitoring (cgm) was comparable to oral glucose tolerance test for diagnosing gestational diabetes and useful in predicting adverse perinatal outcomes. 4. Exercise and glucose control in type 1 diabetes (t1dexi study): this research showed that strategic exercise could reduce hyperglycemia risk without causing hypoglycemia. The study also revealed important sex differences in diabetes self-management strategies. 5. Automated insulin delivery (aid) for older adults: a randomized trial found that older adults with type 1 diabetes significantly benefited from aid systems, experiencing improved glycemic control and enhanced quality of life. 6. Inhaled insulin plus basal insulin vs. Usual care: a randomized trial compared the effectiveness of inhaled insulin combined with basal insulin to standard care in adults with type 1 diabetes. The study found that the combination of inhaled and basal insulin was non-inferior to standard care consisting predominately of either an automated insulin delivery system or multiple daily insulin injections. These findings highlight the potential for inhaled insulin as a viable alternative to traditional rapid-acting insulin therapy and to enhance diabetes management strategies. Eye disease studies: 1. Advanced retinal imaging for diabetic retinop”